Home > Insider Trading > Filing (0001209191-14-077551)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
858803	Avanir Pharmaceuticals Inc.	AVNR	Pharmaceutical Preparations (2834)	330314804

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1534986	Md Joao Siffert	30 Enterprise Suite 400 Aliso Viejo CA 92656	Svp, R&D	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-12-18	32,291	$2.59	348,901	No	4	M	Direct
Common Stock	Disposition	2014-12-18	19,204	$16.99	329,697	No	4	F	Direct
Common Stock	Disposition	2014-12-18	15,505	$16.93	314,192	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2014-12-18	32,291	$0.00	32,291	$2.59

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2022-12-17	No	4	M	Direct

Footnotes

Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. A majority of the proceeds from the sales will be used to pay required withholdings due by the Reporting Person for vesting RSUs.
Represents the weighted-average price at which shares were sold within a range between $16.93 and $16.94. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
The option was granted on 12/17/2012 and vested with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.